- Home
- PMCB
as 12-18-2024 2:41pm EST
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Upcoming Earnings Alert:
Get ready for potential market movements as PharmaCyte Biotech Inc. PMCB prepares to release earnings report on 24 Dec 2024.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | LAGUNA HILLS |
| Market Cap: | 13.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 15.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.39 - $2.58 | Next Earning Date: | 12-24-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest PharmaCyte Biotech Inc. News
PMCB Breaking Stock News: Dive into PMCB Ticker-Specific Updates for Smart Investing
Yahoo Finance Video
6 months ago
FDA panel votes to recommend Eli Lilly's Alzheimer's drug
GlobeNewswire
6 months ago
Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis
Reuters
6 months ago
California seeks company profits in Big Oil climate lawsuit
USA TODAY
6 months ago
S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead
Business Wire
6 months ago
Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock
GlobeNewswire
6 months ago
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
GlobeNewswire
6 months ago
Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research
Business Wire
6 months ago
Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas
Compare PMCB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PMCB PharmaCyte Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.